Literature DB >> 20592467

hNaa10p contributes to tumorigenesis by facilitating DNMT1-mediated tumor suppressor gene silencing.

Chung-Fan Lee1, Derick S-C Ou, Sung-Bau Lee, Liang-Hao Chang, Ruo-Kai Lin, Ying-Shiuan Li, Anup K Upadhyay, Xiaodong Cheng, Yi-Ching Wang, Han-Shui Hsu, Michael Hsiao, Cheng-Wen Wu, Li-Jung Juan.   

Abstract

Hypermethylation-mediated tumor suppressor gene silencing plays a crucial role in tumorigenesis. Understanding its underlying mechanism is essential for cancer treatment. Previous studies on human N-alpha-acetyltransferase 10, NatA catalytic subunit (hNaa10p; also known as human arrest-defective 1 [hARD1]), have generated conflicting results with regard to its role in tumorigenesis. Here we provide multiple lines of evidence indicating that it is oncogenic. We have shown that hNaa10p overexpression correlated with poor survival of human lung cancer patients. In vitro, enforced expression of hNaa10p was sufficient to cause cellular transformation, and siRNA-mediated depletion of hNaa10p impaired cancer cell proliferation in colony assays and xenograft studies. The oncogenic potential of hNaa10p depended on its interaction with DNA methyltransferase 1 (DNMT1). Mechanistically, hNaa10p positively regulated DNMT1 enzymatic activity by facilitating its binding to DNA in vitro and its recruitment to promoters of tumor suppressor genes, such as E-cadherin, in vivo. Consistent with this, interaction between hNaa10p and DNMT1 was required for E-cadherin silencing through promoter CpG methylation, and E-cadherin repression contributed to the oncogenic effects of hNaa10p. Together, our data not only establish hNaa10p as an oncoprotein, but also reveal that it contributes to oncogenesis through modulation of DNMT1 function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20592467      PMCID: PMC2912195          DOI: 10.1172/JCI42275

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  75 in total

1.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

Authors:  Sooryanarayana Varambally; Jianjun Yu; Bharathi Laxman; Daniel R Rhodes; Rohit Mehra; Scott A Tomlins; Rajal B Shah; Uma Chandran; Federico A Monzon; Michael J Becich; John T Wei; Kenneth J Pienta; Debashis Ghosh; Mark A Rubin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

Review 2.  Aberrant DNA methylation as a cancer-inducing mechanism.

Authors:  Manel Esteller
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

3.  Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation.

Authors:  Ji-Hong Lim; Jong-Wan Park; Yang-Sook Chun
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

4.  A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis.

Authors:  Yi Hong; Kok Sun Ho; Kong Weng Eu; Peh Yean Cheah
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

Review 5.  CpG island methylator phenotype in cancer.

Authors:  Jean-Pierre Issa
Journal:  Nat Rev Cancer       Date:  2004-12       Impact factor: 60.716

6.  Active recruitment of DNA methyltransferases regulates interleukin 4 in thymocytes and T cells.

Authors:  Karen W Makar; Mercedes Pérez-Melgosa; Maria Shnyreva; William M Weaver; David R Fitzpatrick; Christopher B Wilson
Journal:  Nat Immunol       Date:  2003-11-02       Impact factor: 25.606

7.  Limited up-regulation of DNA methyltransferase in human colon cancer reflecting increased cell proliferation.

Authors:  P J Lee; L L Washer; D J Law; C R Boland; I L Horon; A P Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

8.  HCMV IE2-mediated inhibition of HAT activity downregulates p53 function.

Authors:  Chih-Hung Hsu; Margaret D T Chang; Kang-Yu Tai; Yu-Ting Yang; Pei-Shan Wang; Chi-Ju Chen; Yan-Hsiung Wang; Sheng-Chung Lee; Cheng-Wen Wu; Li-Jung Juan
Journal:  EMBO J       Date:  2004-05-13       Impact factor: 11.598

9.  LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma.

Authors:  Mojca Strazisar; Vid Mlakar; Damjan Glavac
Journal:  Lung Cancer       Date:  2008-11-12       Impact factor: 5.705

10.  Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation.

Authors:  Y Aylon; N Yabuta; H Besserglick; Y Buganim; V Rotter; H Nojima; M Oren
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

View more
  51 in total

1.  Truncating Variants in NAA15 Are Associated with Variable Levels of Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies.

Authors:  Hanyin Cheng; Avinash V Dharmadhikari; Sylvia Varland; Ning Ma; Deepti Domingo; Robert Kleyner; Alan F Rope; Margaret Yoon; Asbjørg Stray-Pedersen; Jennifer E Posey; Sarah R Crews; Mohammad K Eldomery; Zeynep Coban Akdemir; Andrea M Lewis; Vernon R Sutton; Jill A Rosenfeld; Erin Conboy; Katherine Agre; Fan Xia; Magdalena Walkiewicz; Mauro Longoni; Frances A High; Marjon A van Slegtenhorst; Grazia M S Mancini; Candice R Finnila; Arie van Haeringen; Nicolette den Hollander; Claudia Ruivenkamp; Sakkubai Naidu; Sonal Mahida; Elizabeth E Palmer; Lucinda Murray; Derek Lim; Parul Jayakar; Michael J Parker; Stefania Giusto; Emanuela Stracuzzi; Corrado Romano; Jennifer S Beighley; Raphael A Bernier; Sébastien Küry; Mathilde Nizon; Mark A Corbett; Marie Shaw; Alison Gardner; Christopher Barnett; Ruth Armstrong; Karin S Kassahn; Anke Van Dijck; Geert Vandeweyer; Tjitske Kleefstra; Jolanda Schieving; Marjolijn J Jongmans; Bert B A de Vries; Rolph Pfundt; Bronwyn Kerr; Samantha K Rojas; Kym M Boycott; Richard Person; Rebecca Willaert; Evan E Eichler; R Frank Kooy; Yaping Yang; Joseph C Wu; James R Lupski; Thomas Arnesen; Gregory M Cooper; Wendy K Chung; Jozef Gecz; Holly A F Stessman; Linyan Meng; Gholson J Lyon
Journal:  Am J Hum Genet       Date:  2018-04-12       Impact factor: 11.025

2.  RNA interference screen identifies NAA10 as a regulator of PXR transcription.

Authors:  Peter O Oladimeji; William C Wright; Jing Wu; Taosheng Chen
Journal:  Biochem Pharmacol       Date:  2018-12-16       Impact factor: 5.858

3.  A Saccharomyces cerevisiae model reveals in vivo functional impairment of the Ogden syndrome N-terminal acetyltransferase NAA10 Ser37Pro mutant.

Authors:  Petra Van Damme; Svein I Støve; Nina Glomnes; Kris Gevaert; Thomas Arnesen
Journal:  Mol Cell Proteomics       Date:  2014-01-09       Impact factor: 5.911

4.  Protein N-terminal acetyltransferases act as N-terminal propionyltransferases in vitro and in vivo.

Authors:  Håvard Foyn; Petra Van Damme; Svein I Støve; Nina Glomnes; Rune Evjenth; Kris Gevaert; Thomas Arnesen
Journal:  Mol Cell Proteomics       Date:  2012-10-04       Impact factor: 5.911

5.  Structure and Mechanism of Acetylation by the N-Terminal Dual Enzyme NatA/Naa50 Complex.

Authors:  Sunbin Deng; Robert S Magin; Xuepeng Wei; Buyan Pan; E James Petersson; Ronen Marmorstein
Journal:  Structure       Date:  2019-05-30       Impact factor: 5.006

Review 6.  New roles for old modifications: emerging roles of N-terminal post-translational modifications in development and disease.

Authors:  John G Tooley; Christine E Schaner Tooley
Journal:  Protein Sci       Date:  2014-09-26       Impact factor: 6.725

7.  Host-viral effects of chromatin assembly factor 1 interaction with HCMV IE2.

Authors:  Sung-Bau Lee; Chung-Fan Lee; Derick S-C Ou; Kalpana Dulal; Liang-Hao Chang; Chen-Han Ma; Chien-Fu Huang; Hua Zhu; Young-Sun Lin; Li-Jung Juan
Journal:  Cell Res       Date:  2011-03-29       Impact factor: 25.617

8.  Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency.

Authors:  Alan F Rope; Kai Wang; Rune Evjenth; Jinchuan Xing; Jennifer J Johnston; Jeffrey J Swensen; W Evan Johnson; Barry Moore; Chad D Huff; Lynne M Bird; John C Carey; John M Opitz; Cathy A Stevens; Tao Jiang; Christa Schank; Heidi Deborah Fain; Reid Robison; Brian Dalley; Steven Chin; Sarah T South; Theodore J Pysher; Lynn B Jorde; Hakon Hakonarson; Johan R Lillehaug; Leslie G Biesecker; Mark Yandell; Thomas Arnesen; Gholson J Lyon
Journal:  Am J Hum Genet       Date:  2011-06-23       Impact factor: 11.025

9.  RFTS-deleted DNMT1 enhances tumorigenicity with focal hypermethylation and global hypomethylation.

Authors:  Bo-Kuan Wu; Szu-Chieh Mei; Charles Brenner
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  A splice donor mutation in NAA10 results in the dysregulation of the retinoic acid signalling pathway and causes Lenz microphthalmia syndrome.

Authors:  Taraneh Esmailpour; Hamidreza Riazifar; Linan Liu; Sandra Donkervoort; Vincent H Huang; Shreshtha Madaan; Bassem M Shoucri; Anke Busch; Jie Wu; Alexander Towbin; Robert B Chadwick; Adolfo Sequeira; Marquis P Vawter; Guoli Sun; Jennifer J Johnston; Leslie G Biesecker; Riki Kawaguchi; Hui Sun; Virginia Kimonis; Taosheng Huang
Journal:  J Med Genet       Date:  2014-01-15       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.